jcp conference-coverage

Conference Coverage

Videos

AMCCBS Preview: Focus on Collaboration and New Trends in Oncology Care

02/26/2024

Featuring James Hamrick, MD

James Hamrick, MD, vice president of clinical oncology at Flatiron Health, gives a preview of the most compelling themes and sessions from the Association of Cancer Care Centers 50th Annual Meeting & Cancer Center Business Summit in...

James Hamrick, MD, vice...

02/26/2024

Journal of Clinical Pathways

Videos

Highlights and Key Takeaways in Prostate Cancer From ASCO GU 2024

02/15/2024

Featuring Alexandra Sokolova, MD

Featuring Alexandra Sokolova, MD ...

Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.

Alexandra Sokolova, MD, shares...

02/15/2024

Journal of Clinical Pathways

News

Treatment Patterns and Overall Survival for Patients With Metastatic Urothelial Carcinoma Following FDA Approval of Avelumab Maintenance Therapy

02/15/2024

Grace Taylor

A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.

A study by Haojie Li, MD, PhD,...

02/15/2024

Journal of Clinical Pathways

News

Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features

02/14/2024

Grace Taylor

A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...

A recent study investigated...

02/14/2024

Journal of Clinical Pathways

Videos

AI in Health Care: Foundations, Myths, and Practical Applications

02/07/2024

Featuring Ira Klein, MD, MBA

Ira Klein, MD, MBA, vice president of medical affairs for Tempus Labs, provides insight into the future of AI in health care and how it will help cut down on mundane tasks and increase oncologists’ efficiency.

Ira Klein, MD, MBA, vice...

02/07/2024

Journal of Clinical Pathways

News

The Use of Geriatric Assessment in Predicting Toxicities in Older Adults with Non-Hodgkin Lymphoma Receiving Systemic Chemotherapy

02/06/2024

Grace Taylor

Pallawi Torka, MD, and colleagues investigated whether a geriatric assessment or its component measures can predict toxicity in older adults with non-Hodgkin lymphoma.

Pallawi Torka, MD, and...

02/06/2024

Journal of Clinical Pathways

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

Featuring Andrea Apolo, MD

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/31/2024

Stephanie Holland

Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.

Long-term follow-up data from...

01/31/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

Featuring David Aggen, MD, PhD

Featuring David Aggen, MD, PhD ...

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

News

Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma

01/30/2024

Grace Taylor

Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

Jennifer L. Crombie, MD, and...

01/30/2024

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products